All posts by imreal

22,860 SARS-CoV-2 coronavirus tests in 24 hours with NEXTGENPCR


“We sought to decrease what we identified as the longest step in the current testing scheme, amplification.” – Gert de Vos, MBS CEO and founder

Dutch biotechnology company, Molecular Biology Systems, B.V. (MBS) has developed a method using its revolutionary NEXTGENPCR endpoint thermocycler and consumables that decreases PCR amplification time for SARS-CoV-2 to eight minutes. Combined with smaller reaction volumes, increased samples per run, and standard, affordable laboratory equipment, a qualitative protocol was generated that could readily detect SARS-CoV-2 control DNA, with equivalent sensitivity. A single unit, the size of a shoebox, could perform a hundred and eighty (180) amplification runs a day, an almost ten-fold increase over the current US Centers for Disease Control (CDC) recommended instrumentation. Detection of amplified product can be done with widely-available blue light gel document systems.

“We sought to decrease what we identified as the longest step in the current testing scheme, amplification,” says MBS CEO and founder, Gert de Vos. “We started with the CDC assay because it is well characterized and has been readily available.”

Since the NEXTGENPCR accepts both 96 and 384-well reaction plates, MBS tested both versions to increase throughput. By utilizing 384-well plates, the machine successfully processed four times as many samples without a loss in performance. The 384-well reaction chambers only require twenty-five percent of the reaction volume which would lower the supply burden placed on laboratories following the current CDC protocol.

NEXTGENPCR machines launched about two years ago and are available globally. Gert de Vos stated, “This protocol produces a simple yes/no answer — so a single machine, is capable of running 24/7, with 8-minute runs may provide a scalable screening solution analyzing 22,860 samples per day.”

MBS is now collaborating with testing laboratories in the USA and the Netherlands to transfer and validate the method.

Find out more at http://www.nextgenpcr.com

About Molecular Biology Systems

Molecular Biology Systems, B.V., founded in 2015, is a molecular biology solutions company based in Netherlands. Their NEXTGENPCR thermocycler uses patented heating and cooling technology to reduce PCR amplification cycles from hours to minutes. These technological advances are intended to support laboratorians across the life sciences market reduce costs and accelerate results.

All referenced product names, and other marks, are trademarks of their respective owners.

© 2020 Molecular Biology Systems, B.V. All rights reserved.

Share article on social media or email:

COVID-19 by Hayver Launches Comprehensive Solution to Monitor and Hold Accountable Populations in the COVID-19 Pandemic


News Image

We are concentrating all of our efforts on making our solutions available to health authorities fighting against this pandemic.

COVID-19 by Hayver announces the launch of a comprehensive, end-to-end solution utilizing smartphone technology, metadata and predictive analytics to stop the spread of COVID-19 and help people to go safely back to work. COVID-19 by Hayver monitors, tracks and holds accountable populations, while respecting privacy, in order to 1) mitigate COVID-19 community spread, 2) protect vulnerable populations, 3) manage quarantines and isolations, 4) monitor viral expansion so resources can be applied in a directed fashion and 5) enable society to go back to normal in a controlled manner, once the viral expansion has been contained.

“We are concentrating all of our efforts on making our solutions available to health authorities fighting against this pandemic,” Hayver CEO Barry Hayut said. “We believe that we have the platform to dramatically load-balance their work, and ensure their efforts are efficient in regards to protecting the population and stopping the spread of COVID-19.”

Hayver’s solution includes a Daily Diary screening tool that collects HIPAA-compliant data points for COVID-19 tracking and management. Members will check in daily and relay information such as any symptoms of fever, cough or difficulty breathing, along with any possible contact with a COVID-19 infected-person. Users are asked additional questions regarding feelings of confusion, difficulty waking up, or any new or developing aches and pains, and more.

As well, the platform’s GPS tracking ability allows for contact tracing, which permits healthcare professionals to more easily track the spread of the infection and understand who has recovered, who is infectious and who is trending towards becoming infected.

Hayver has also embedded into the COVID-19 by Hayver system its Circle of Support program to allow participants to include family members or individuals living in the same household, and contacts, who can be notified about any changes concerning their health status. This Early Warning System helps the user and their family to identify possible cross-infection situations and then be able to notify the proper health authorities to receive prioritized care.

Hayut has gone on to say, “This COVID-19 system by Hayver provides information to the patient about their best ‘next steps’, based on their exposure and symptomatology; additionally, by aggregating the information from many individuals in a geographic area, healthcare organizations and governments can predict resource requirements and load balance the requirements with the available supplies and personnel. By providing real-time phone-location data, and geo-fencing, to track the movements of virus carriers and the people they come in contact with, containment and flattening of the curve is potentially within our grasp.”

Whether it’s going in to obtain urgent care, being in quarantine, isolating from others, wearing a face mask, or social distancing, the science drives the recommendation and the individual can be optimally informed so they can take the appropriate precautions. With the ability to provide testing advice and alter these parameters as we learn more, COVID-19 by Hayver informs the individual when and where to be tested, and ensures that the right people are able to obtain access to limited resources.

Through anonymized data, Health Authorities can also better understand where infections are growing or peaking, how they are spreading (travel vs. community), if travelers are abiding by self-isolation protocols, and when wholesale policies such as mass quarantines need to be implemented to forestall the spread of COVID-19.

Contact tracing is a critical component of dampening the viral spread; and the average person cannot possibly know or remember everywhere they have traveled in the last two weeks. Identification and notification can be done anonymously, to ensure privacy and still support public health goals.

The platform also enables healthcare professionals to communicate with the user in one-on-one or one-on-many telecommunication sessions to provide treatment information, as well as educational and instructional information — or area-wide alerts or warnings. Additional informational content, such as videos and documents, can be distributed through the platform to help facilitate the flow of information to the user. The platform allows professionals to distribute information easily, saving them time and easing the workload on healthcare workers.

Since 2017, Hayver has operated a HIPAA-compliant, smart phone-based population monitoring and accountability app, with a complete analytical, predictive platform to monitor and change health-related behaviors. The company has developed and successfully tested in “real life” the monitoring system for one of the least compliant populations: alcohol and drug addicts.

For more information, contact:

Barry Hayut, Co-Founder, CEO

BHayut@Hayver.com

Phone number: 678-701-9122

Share article on social media or email:

NeoTract Designates Dr. Philip Brodak as UroLift® Center of Excellence


News Image

“Dr. Philip Brodak has earned the UroLift Center of Excellence designation for his dedication to improving the lives of men who previously suffered from BPH symptoms and delivering superior patient outcomes with the UroLift System treatment,” said Dave Amerson

NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced that Philip Brodak, M.D., Tri Valley Urology in Murrieta, CA, has been designated as a UroLift® Center of Excellence. The designation recognizes that Dr. Brodak has achieved a high level of training and experience with the UroLift® System and demonstrated a commitment to exemplary care for men suffering from symptoms associated with Benign Prostatic Hyperplasia (BPH), also known as enlarged prostate.

Recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines, the FDA-cleared Prostatic Urethral Lift procedure using the UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to BPH. The UroLift permanent implants, delivered during a transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue.

The UroLift Center of Excellence program is designed to highlight urologists who are committed to educating their patients on BPH and the UroLift System as a treatment option and consistently seek to deliver excellent patient outcomes and experiences.

“Dr. Philip Brodak has earned the UroLift Center of Excellence designation for his dedication to improving the lives of men who previously suffered from BPH symptoms and delivering superior patient outcomes with the UroLift System treatment,” said Dave Amerson, president of the Teleflex Interventional Urology business unit.

Over 40 million men in the United States are affected by BPH, a condition that occurs when the prostate gland that surrounds the male urethra becomes enlarged with advancing age and begins to obstruct the urinary system. Symptoms of BPH often include interrupted sleep and urinary problems and can cause loss of productivity, depression and decreased quality of life.

Medication is often the first-line therapy for enlarged prostate, but relief can be inadequate and temporary. Side effects of medication treatment can include sexual dysfunction, dizziness and headaches, prompting many patients to quit using the drugs. For these patients, the classic alternative is surgery that cuts, heats or removes prostate tissue to open the blocked urethra. While current surgical options can be very effective in relieving symptoms, they can also leave patients with permanent side effects such as urinary incontinence, erectile dysfunction, and retrograde ejaculation.

About the UroLift® System

The FDA-cleared UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function*1,2. Patients also experienced a significant improvement in quality of life. Over 100,000 men have been treated with the UroLift System in the U.S. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure. The Prostatic Urethral Lift procedure using the UroLift System is recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines. The UroLift System is available in the U.S., Europe, Australia, Canada, Mexico and South Korea. Learn more at http://www.UroLift.com.

About NeoTract | Teleflex Interventional Urology

A wholly owned subsidiary of Teleflex Incorporated, the Interventional Urology Business Unit is dedicated to developing innovative, minimally invasive and clinically effective devices that address unmet needs in the field of urology. Our initial focus is on improving the standard of care for patients with BPH using the UroLift System, a minimally invasive permanent implant system that treats symptoms while preserving normal sexual function*1,2. Learn more at http://www.NeoTract.com.

About Teleflex Incorporated

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit http://www.teleflex.com.

Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rusch®, UroLift® and Weck® – trusted brands united by a common sense of purpose

# # #

For Teleflex Incorporated:

Jake Elguicze, 610.948.2836

Treasurer and Vice President, Investor Relations

Media:

Nicole Osmer, 650.454.0504 nicole@healthandcommerce.com

*No instances of new, sustained erectile or ejaculatory dysfunction

1. Roehrborn, J Urology 2013 LIFT Study

2.McVary, J Sex Med 2016

MAC00968-01 Rev A

Share article on social media or email:

Corsa Security Appoints Claudio Perugini as Chief Revenue Officer


Corsa Security Appoints Claudio Perugini as Chief Revenue Officer

I’m excited to join the innovative, dedicated team at Corsa Security. Their revolutionary approach to scale network security and give enterprises the ability to gain 100% traffic inspection can be a real game changer.

Corsa Security today announced it has appointed Claudio Perugini as its Chief Revenue Officer. With over 30 years’ executive leadership experience in enterprise security, software and networking markets, Perugini has gained a reputation for building, driving and motivating sales teams and channel partners to grow revenue. He will work with CEO, Eduardo Cervantes to strengthen the sales team, optimize new business opportunities and deepen relationships with strategic partners.

As an accomplished and highly qualified sales executive, Perugini has been instrumental in the start-up, growth, turnaround and optimization of businesses like Gigamon, where he grew revenue in the Americas by 10 fold and led it through a successful IPO. As Executive Vice President of Global Sales at LightCyber, Perugini was responsible for the buildout of global sales, channel and field engineering teams, contributing to the company’s overall growth and resulting acquisition by Palo Alto Networks in 2017. In addition, Perugini was a founding member of Fluke Networks, a division of Danaher, where he held several sales leadership roles helping them grow from startup to a $500 million division. You can learn more on LinkedIn.

“Claudio’s appointment is a significant step in our company’s expansion,” said Eduardo Cervantes, President and CEO, Corsa Security. “He has a strong background of successfully growing many businesses, establishing strategic partnerships with key channels, and developing excellent customer relationships and loyalty.”

“I’m excited to join the innovative, dedicated team at Corsa Security,” said Claudio Perugini. “Their revolutionary approach to scale network security and give enterprises the ability to gain 100% traffic inspection can be a real game changer. Some sales executives build and lay the train tracks, some ride on the tracks that others build. I empower people by building teams that can go on to build and lay new tracks, leading to sustainable growth.”

Corsa Security has been gaining significant momentum over the past year with the launch of its turnkey Network Security Virtualization Platform, establishing key partnerships with both Fortinet and Palo Alto Networks and working to expand its Network Security Ecosystem by signing several Channel Partners. They have also announced key customer wins such as Recoletas Red Hospitalaria.

About Corsa Security

Corsa Security is the leader in scaling network security with the first turnkey network security virtualization platform that simplifies how large enterprises and service providers scale traffic inspection, including SSL/TLS encrypted, at much lower total cost of ownership (TCO). By tightly integrating virtualization with intelligent orchestration, Corsa Security streamlines deployment, management and operations of virtualized next generation firewall (NGFW) arrays for large networks. Customers subscribe to the Corsa Security service based on their traffic inspection capacity needs and then pay as they grow while never having to deal with the infrastructure. Learn how Corsa Security is revolutionizing network security at corsa.com.

Share article on social media or email:

Estate Planning Platform Willful Offers Free Wills & POA Documents to Frontline Healthcare Workers


willful wills power of attorney POA COVID-19

Willful Launches Free Wills for Healthcare Workers

We’ve seen an increasing number of Canadians discussing end-of-life planning with loved ones and turning to tools like Willful to complete their estate plan while social distancing, and we hope this makes it easier for healthcare workers to get these documents finalized.

Today Toronto-based estate planning platform Willful announced it has partnered with U.S.-based Trust & Will to offer thousands of free wills and Power of Attorney documents to frontline healthcare workers in the U.S. and Canada who are working in hospitals and urgent care centres treating COVID-19. Healthcare administrators in both countries have called for doctors, nurses, and other frontline healthcare professionals to get these documents in order since their jobs result in higher exposure to the virus. Online platforms like Willful and Trust & Will make it easy for anyone to create a legally-binding will and Power of Attorney documents online in less than 20 minutes, giving healthcare workers an easy way to complete these documents without having to visit a lawyer. An AngusReid survey conducted by Willful showed that 57% of Canadian adults don’t have a will, of those who do, 10% are out-of-date.

“We’re incredibly grateful to the healthcare workers who are risking their lives to keep us safe, and as a Canadian small business, we wanted to do whatever we could to help our local frontline workers who are treating COVID-19 patients,” said Erin Bury, co-founder & CEO, Willful. “We’ve seen an increasing number of Canadians discussing end-of-life planning with loved ones and turning to tools like Willful to complete their estate plan while social distancing, and we hope this makes it easier for healthcare workers to get these documents finalized.”

Willful launched in 2017 and has helped thousands of Canadians create their wills and Power of Attorney documents from home. The platform offers three plans catered to singles and couples ranging from $99-249, and as part of this initiative the company will be giving away 1,000 of its Premium plans, each valued at $149, until April 30. The Premium plan comes with three documents: a will, which allows users to plan for what happens when they pass away, and two Power of Attorney documents, which allow users to appoint someone to make medical and financial decisions in case they become incapacitated. Each plan also comes with free will registry on the CanadaWillRegistry, a $35 value.

Canadian law requires that wills are printed, signed, and witnessed correctly in order to be legally-valid, which presents challenges for anyone social distancing, self-isolating, or quarantining. Since many Canadians have lost access to a printer, Willful is offering free printing and shipping of documents for a limited time. The company also created a guide outlining how to get a will signed and witnessed during COVID-19. Recognizing the limitations in current laws, Willful partner NoticeConnect, the owner of the CanadaWillRegistry, launched a petition to amend the law to recognize virtual witnesses to address this issue.

Willful is available in seven Canadian provinces, and the company has partnered with San Diego-based Trust & Will to refer customers to each other’s services. Trust & Will’s modern estate planning platform is available nationwide, and executed the first digital Will (eWill) in 2019 in Nevada. Several U.S. states now allow for the digital signing of Wills. Trust & Will is offering free Wills, Power of Attorney, and Healthcare Directive documents to frontline healthcare workers in the U.S., where COVID-19 cases are now the highest globally.

“As a husband to a spouse who works in a hospital, and whose colleagues are like family to us, it hit close to home seeing the risk that healthcare professionals are putting themselves in every day right now. The last thing that should be weighing down on any healthcare professional, especially if they are a parent, is not having an estate plan in place,” said Cody Barbo, CEO, Trust & Will. “We are grateful to be working with our friends to the North at Willful, to help spread the word about their offer to help Canadian healthcare professionals. We are all in this together!”

To learn more about Willful’s initiative for healthcare workers, visit willful.co/support-healthcare

To learn more about Trust & Will’s initiative for healthcare workers, visit trustandwill.com/frontline-heroes

About Willful

Willful’s mission is to change the way Canadians prepare for and deal with death. Their first product is an online platform that makes it affordable, convenient, and easy for Canadians to create a legal will online. The platform provides simplified estate planning services (creation of a Legal Will and Power of Attorney documents), enabling consumers to create a will and/or power of attorney by following a clear step-by-step process. Willful’s platform was developed in collaboration with leading estate lawyers, with pricing plans starting at $99. Willful is based in Toronto, and it is currently available to residents of Ontario, British Columbia, Saskatchewan, Manitoba, Alberta New Brunswick, and Nova Scotia.

Share article on social media or email:

Softtek to Host Webcast on CIO Strategies to Increasing Challenges for the “New Normal”


WHAT: Softtek, a global company dedicated to helping organizations evolve through digital technology, to present a live webinar entitled “Leading in uncertain times: A look into the shifting demands on the technology organization.”

WHEN:

March 31st, 2pm ET / 11am PT

WHY ATTEND:

CIOs are dealing with massively competing priorities through a transition to an unprecedented business situation. Specifically, there are increasing pressures to: (1) reduce costs; (2) enable remote workers in a way that preserves productivity and security; (3) maintain the digital gains (including the digital IT workforce) they’ve already achieved; and (4) alter existing digital channels to accommodate new social distancing needs. The session will share strategies CIOs are putting in place to balance mounting requirements. These include digital cost take-out approaches that lead to a stronger foundation for future digital development as things settle into a “new normal.”

Attendees will learn strategies for:

  • Empowering the new remote workforce (Talent)
  • Reducing disruptions and stabilizing operations (Continuity)
  • Enhancing and expanding digital channels (Revenue)
  • Rapidly reducing waste and overcapacity (Costs)
  • Getting ready to lead as a ‘new normal’ arrives (Future)

Speakers:

  • Stephanie Moore, SVP Marketing, Softtek and former Forrester Analyst
  • John Seral, Operating Advisor, Clayton Dubilier & Rice
  • Vince Chapa, SVP of Sales, Softtek
  • Beni Lopez, Managing Director, Industrial & US Market, Softtek
  • Alex Camino, CMO, Softtek
  • Jaime Palacios, SVP, Digital & Innovation, Softtek

Learn more and register for the webcast here.

About Softtek:

Founded in 1982, Softtek is a global company and the largest provider of IT services from Latin America. With a broad portfolio of business-transforming products and solutions, Softtek helps Global 2000 organizations evolve their digital capabilities constantly and seamlessly, from ideation and development to execution. Learn how Softtek creates value through technology at http://www.softtek.com and connect with @Softtek in social media.

For more information, contact:

Karen Liedl

Softtek

karen.liedl@softtek.com

+1-763-291-1464

Share article on social media or email:

Advera Health Analytics Brings Drug Safety Data to the Open:FactSet Marketplace


Advera Health Analytics, a market leader in cloud based software and data-as-a-service drug safety solutions, today announced the launch of its data on the Open:FactSet Marketplace™ (OFM).

The OFM will feature Advera’s proprietary FDA Adverse Event Reporting System (FAERS) data. FAERS is the U.S. national database containing information on drug adverse events and medication errors voluntarily reported to FDA about marketed drugs. Advera is a market leader in providing optimized and cleansed FAERS data, statistical analysis, and critical workflow tools to pharmaceutical companies, financial institutions, and large healthcare providers.

Advera’s FAERS database contains over 12 million adverse drug event reports, with 1.5 million events reported in 2019 alone. Every adverse drug event report is mapped to the appropriate pharmaceutical company, drug, condition, indication, and mechanism of action and also contains de-identified patient demographic data. Drug label information and statistical calculations of disproportionate reporting are also provided. OFM clients will be able to use Advera’s data in combination with other OFM data sources to power quantitative models for the biopharmaceutical sector.

“Post-marketing adverse event data can be used as a leading indicator for a variety of market triggers”, said Brian Overstreet, President and CEO of Advera Health. “Regulatory authorities and pharmaceutical companies have long used advanced analytics with FAERS data to detect emerging drug safety issues in approved drugs. Our collaboration with FactSet will allow us to not only deliver these data to a broader set of global organizations, but will open opportunities to combine with other OFM datasets to better understand, develop, and refine strategies in the biopharmaceutical sector.”

About Advera Health Analytics

Advera Health Analytics is a global leader in pharmacovigilance software, analytics, and data at the leading edge of drug safety science. Advera Health has created Evidex, a next generation pharmacovigilance platform to connect disparate drug safety data sources and provide a user experience that elicits actionable intelligence from those data. The Evidex platform links to internal ICSR databases, FAERS, VigiBase, and other data and provides for a validated, audit ready environment to track and manage safety issues that are found in those data. Founded by a group of passionate healthcare entrepreneurs, Advera Health’s mission is to mitigate risk in the healthcare system by improving the transparency and actionability of drug safety data through the curation and aggregation of large disparate datasets and the application of advanced analytics and workflow. Please visit http://www.adverahealth.com as well as our newsroom, blog, Twitter, and LinkedIn pages for more information about the company.

Share article on social media or email:

Debbie Fiorino Named an Influential Business Woman by South Florida Business Journal


Debbie Fiorino was named a 2020 Influential Business Woman by South Florida Business Journal.

Being an Influential Business Woman extends beyond the boardroom, it is about being a role model, a calming voice of reason in times of uncertainty and inspiring others to persevere as we will all come out stronger on the other side.

Dream Vacations, CruiseOne® and Cruises Inc.® Chief Operating Officer Debbie Fiorino was recently named an Influential Business Woman by South Florida Business Journal. Honorees have strong records of leadership, performance and innovation in their industries plus meaningful community involvement.

“2020 has been a roller coaster of a year and while being recognized as an Influential Business Woman is always an honor, this recognition is even more meaningful today as we are all navigating through unforeseen circumstances impacting the world we live in,” said Fiorino. “To me, being an Influential Business Woman extends beyond the boardroom, it is about being a role model, a calming voice of reason in times of uncertainty and inspiring others to persevere as we will all come out stronger on the other side.”

Fiorino was honored for her dynamic personality and servant leadership; she not only changed the company culture, but also made the division experience incredible growth year-after-year since taking over in 2014. Her influence extends beyond Dream Vacations, CruiseOne and Cruises Inc., through her extensive community involvement and her advocacy for travel agents nationwide, which is more prevalent and important than ever before.

This recognition comes on the heels of several other accolades Fiorino received early this year, including being name a Power Woman by Moves magazine and a Woman of Wonder by Franchise Dictionary magazine.

To learn more about the CruiseOne / Dream Vacations travel agency franchise opportunity, please visit http://www.dreamvacationsfranchise.com, and visit http://www.sellcruises.com to learn more about the Cruises Inc. business opportunity.

About Dream Vacations, CruiseOne® and Cruises Inc.®

Dream Vacations, CruiseOne® and Cruises Inc.® are part of World Travel Holdings, the nation’s largest cruise agency and award-winning leisure travel company. The Dream Vacations and CruiseOne franchise opportunities give entrepreneurs a choice in how they want to brand their travel business, and Cruises Inc. is an independent business opportunity. Both business models provide a work-from-home opportunity to those interested in selling all types of travel experiences whether it be a cruise, resort stay or land tour. With a mission of delivering a remarkable experience, travel agents with all three brands are given premium resources to plan and create a seamless vacation experience for the customer while offering the best value. For more information on Dream Vacations and CruiseOne, visit http://www.DreamVacationsFranchise.com, like the Facebook page http://www.facebook.com/DreamVacationsFranchise, follow on Twitter at @Dream_Franchise or watch its videos at http://www.youtube.com/DreamVacationsBusiness. For more information on Cruises Inc., visit http://www.SellCruises.com and become a fan on Facebook at http://www.facebook.com/SellCruises.

Share article on social media or email:

Procap Medical Billing, LLC announces Free 2020 Consultations


Karina Pismichenko knows that medical professionals, such as family physicians, are not only some of the most needed types of physicians in the U.S., but are also ones that need help from medical billers frequently.

Karina Pismichenko knows that medical professionals, such as family physicians, are not only some of the most needed types of physicians in the U.S., but are also ones that need help from medical billers frequently. These physicians are always on-call, and without them many children and parents alike couldn’t get the immediate attention they need at home. Our entire society depends on family physicians so much, so why should they have to struggle when it is time for them to be paid for their services? This is why Ms. Pismichenko’s Staten Island based Procap Medical Billing is making sure that no-cost consultations are available this year for them, as well as all other physicians and medical clinics and hospitals in and around the area.

Another type of physician that Karina Pismichenko realizes needs her medical billing services greatly right now are pediatricians. With the recent appearance of COVID-19 aka the Coronavirus, many parents want to be sure that their children are staying healthy. With so many kids out of school and now at home, pediatricians are currently even busier with the role of home visits, and don’t have time to put extra energy into tracking down reimbursements for their medical services, networking with insurance companies, etc.

Medical billing services like Karina Pismichenko’s makes the payment process fluid, and does all the necessary networking that clinics and physicians just don’t have the time to do. They deserve to be represented by a medical billing service that will allow them the peace of mind they need to do what they do best, and that is to make sure that the general public stays healthy. Now is the time to contact Ms. Karina Pismichenko, owner of Staten Island’s Procap Medical Billing, LLC for an absolutely free consultation, to ensure that all of your reimbursement worries are over.

Share article on social media or email:

DuPont Announces Exclusive Agreement of Toyobo’s PBO for Emergency Response Market


News Image

The need for functional, comfortable and durable PPE has never been more paramount in the ER industry and we are proud to manufacture and provide the latest protective apparel to ER teams to ensure they are confident about their safety when addressing the community’s safety.

DuPont Specialty Products Kabushiki Kaisha, through its Safety & Construction business (DuPont), announced it has reached a joint agreement with TOYOBO CO., LTD. (Toyobo) in which DuPont secures the exclusive global marketing and distribution rights of PBO staple fiber to the Emergency Response (ER) market. Financial terms of the agreement were not disclosed.

The global market for firefighter clothing is expected to continue to grow thanks in part to expanding markets in China and India. With this new agreement, DuPont will work to support the development of new, innovative protective clothing fabrics for the ER market that will take advantage of the combined individual characteristics of DuPont™ Kevlar®, Nomex® and PBO staple fiber.

Toyobo and DuPont are confident that the use of PBO staple fiber will enable the development and supply of next-generation firefighter garments that are functional, lightweight, durable and possess super heat-resistant properties.

“We’re excited to partner with Toyobo; working together to innovate on behalf of firefighters and emergency response teams,” said John Richard, Vice President & General Manager at DuPont Safety & Construction. “The need for functional, comfortable and durable personal protective equipment has never been more paramount in the ER industry and we are proud to manufacture and provide the latest protective apparel to ER teams to ensure they are confident about their safety when addressing the community’s safety.”

PBO features one of the world’s highest levels of strength, tensile modulus and flame resistance among organic fibers and has been used in the high-performance outer shell application for more than 10 years. With DuPont and Toyobo’s partnership solidified, DuPont will leverage PBO to complement the company’s high-performance outer shells for firefighter turnout gear.

For more than 50 years, DuPont has been committed to helping protect firefighters and other first responders with science-based innovations such as Kevlar® and Nomex® fibers, which provide proven protection, durability and comfort from the inside out.

About DuPont Safety & Construction

DuPont Safety & Construction is a global leader in delivering innovation for life’s essential needs in water, shelter and safety; enabling its customers to win through unique capabilities, global scale and iconic brands including Corian®, Kevlar®, Nomex®, Tyvek®, GreatStuff™, Styrofoam™ and Filmtec®.

About DuPont

DuPont (NYSE: DD) is a global innovation leader with technology-based materials, ingredients and solutions that help transform industries and everyday life. Our employees apply diverse science and expertise to help customers advance their best ideas and deliver essential innovations in key markets including electronics, transportation, construction, water, health and wellness, food and worker safety. More information can be found at http://www.dupont.com.

Cautionary Statement Regarding Forward Looking Statements

This communication contains “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “see,” “will,” “would,” “target,” and similar expressions and variations or negatives of these words.

On April 1, 2019, the company completed the separation of its materials science business into a separate and independent public company by way of a pro rata dividend-in-kind of all the then outstanding stock of Dow Inc. (the “Dow Distribution”). The company completed the separation of its agriculture business into a separate and independent public company on June 1, 2019, by way of a pro rata dividend-in-kind of all the then outstanding stock of Corteva, Inc. (the “Corteva Distribution”).

On December 15, 2019, DuPont and IFF announced they had entered definitive agreements to combine DuPont’s Nutrition & Biosciences business with IFF in a transaction that would result in IFF issuing shares to DuPont shareholders, pending customary closing conditions, other approvals including regulatory and that of IFF’s shareholders.

Forward-looking statements address matters that are, to varying degrees, uncertain and subject to risks, uncertainties and assumptions, many of which that are beyond DuPont’s control, that could cause actual results to differ materially from those expressed in any forward-looking statements. Forward-looking statements are not guaranties of future results. Some of the important factors that could cause DuPont’s actual results to differ materially from those projected in any such forward-looking statements include, but are not limited to: (i) the parties’ ability to meet expectations regarding the timing, completion and accounting and tax treatments of the proposed transaction with IFF; changes in relevant tax and other laws, (ii) failure to obtain necessary regulatory approvals, approval of IFF’s shareholders, anticipated tax treatment or any required financing or to satisfy any of the other conditions to the proposed transaction with IFF, (iii) the possibility that unforeseen liabilities, future capital expenditures, revenues, expenses, earnings, synergies, economic performance, indebtedness, financial condition, losses, future prospects, business and management strategies that could impact the value, timing or pursuit of the proposed transaction with IFF, (iv) risks and costs and pursuit and/or implementation of the separation of the N&B Business, including timing anticipated to complete the separation, any changes to the configuration of businesses included in the separation if implemented, (v) risks and costs related to the Dow Distribution and the Corteva Distribution (together, the “Distributions”) including (a) with respect to achieving all expected benefits from the Distributions; (b) the incurrence of significant costs in connection with the Distributions, including costs to service debt incurred by the Company to establish the relative credit profiles of Corteva, Dow and DuPont and increased costs related to supply, service and other arrangements that, prior to the Dow Distribution, were between entities under the common control of DuPont; (c) indemnification of certain legacy liabilities of E. I. du Pont de Nemours and Company (“Historical EID”) in connection with the Corteva Distribution; and (d) potential liability arising from fraudulent conveyance and similar laws in connection with the Distributions; (vi) failure to effectively manage acquisitions, divestitures, alliances, joint ventures and other portfolio changes, including meeting conditions under the Letter Agreement entered in connection with the Corteva Distribution, related to the transfer of certain levels of assets and businesses; (vii) uncertainty as to the long-term value of DuPont common stock; (viii) potential inability or reduced access to the capital markets or increased cost of borrowings, including as a result of a credit rating downgrade and (ix) other risks to DuPont’s business, operations and results of operations including from: failure to develop and market new products and optimally manage product life cycles; ability, cost and impact on business operations, including the supply chain, of responding to changes in market acceptance, rules, regulations and policies and failure to respond to such changes; outcome of significant litigation, environmental matters and other commitments and contingencies; failure to appropriately manage process safety and product stewardship issues; global economic and capital market conditions, including the continued availability of capital and financing, as well as inflation, interest and currency exchange rates; changes in political conditions, including tariffs, trade disputes and retaliatory actions; impairment of goodwill or intangible assets; the availability of and fluctuations in the cost of energy and raw materials; business or supply disruption, including in connection with the Distributions; ability to effectively manage costs as the company’s portfolio evolves; security threats, such as acts of sabotage, terrorism or war, global health concerns and pandemics, natural disasters and weather events and patterns which could result in a significant operational event for DuPont, adversely impact demand or production; ability to discover, develop and protect new technologies and to protect and enforce DuPont’s intellectual property rights; unpredictability and severity of catastrophic events, including, but not limited to, acts of terrorism or outbreak of war or hostilities, as well as management’s response to any of the aforementioned factors. These risks are and will be more fully discussed in DuPont’s current, quarterly and annual reports and other filings made with the U.S. Securities and Exchange Commission, in each case, as may be amended from time to time in future filings with the SEC. While the list of factors presented here is considered representative, no such list should be considered a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on DuPont’s consolidated financial condition, results of operations, credit rating or liquidity. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. DuPont assumes no obligation to publicly provide revisions or updates to any forward-looking statements whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws. A detailed discussion of some of the significant risks and uncertainties which may cause results and events to differ materially from such forward-looking statements is included in the section titled “Risk Factors” (Part I, Item 1A) of DuPont’s Annual Report on Form 10-K as updated by DuPont’s subsequent periodic and current reports filed with the SEC.

# # #

3/31/2020

DuPont™, the DuPont Oval Logo, and all trademarks and service marks denoted with ™, ℠ or ® are owned by affiliates of DuPont de Nemours, Inc. unless otherwise noted.